Journals / art / 2018 / Cilt: 33 - Sayı: 3

Pneumatosis Intestinalis and Intestinal Perforation in a Patient Receiving Tocilizumab

Journal
art
Pages
372–375
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This is a unique case and may explain the increased rate of idiopathic bowel perforation among patients taking tocilizumab.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this article, we report a case of pneumatosis intestinalis associated with tocilizumab use.
📊
Key Findings & Data:In this article, we report a case of pneumatosis intestinalis associated with tocilizumab use.
💡
Conclusion & Impact:This is a unique case and may explain the increased rate of idiopathic bowel perforation among patients taking tocilizumab.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

In this article, we report a case of pneumatosis intestinalis associated with tocilizumab use. This is a unique case and may explain the increased rate of idiopathic bowel perforation among patients taking tocilizumab.

🔖

Cite This Article

JACOBS, B., JAWAD, A., FATTAH, Z. (2018). Pneumatosis Intestinalis and Intestinal Perforation in a Patient Receiving Tocilizumab. art, Cilt: 33 - Sayı: 3, 372–375. https://ajindex.com/articles/158136

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Conway R, Orr C, McCarthy GM. Lesson of the month 1: Septic arthritis with normal acute phase reactants and white cell count in a patient receiving tocilizumab. Clin Med (Lond) 2017;17:280-1.
  2. Strangfeld A, Richter A, Siegmund B, Herzer P, Rockwitz K, Demary W, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis 2017;76:504-10.
  3. Imai K, Doi Y, Takata N, Yoshinaka I, Harada K. Successful conservative treatment of pneumatosis intestinalis associated with intraperitoneal free air: report of a case. Surg Today 2012;42:992-6.
  4. Schulenburg A, Herold C, Eisenhuber E, Oberhuber G, Volc-Platzer B, Greinix HT, et al. Pneumatosis [correction of Pneumocystis] cystoides intestinalis with pneumoperitoneum and pneumoretroperitoneum in a patient with extensive chronic graft-versus-host disease. Bone Marrow Transplant 1999;24:331-3.
  5. Daly BD, Guthrie JA, Couse NF. Pneumoperitoneum without peritonitis. Postgrad Med J 1991;67:9991003. St Peter SD, Abbas MA, Kelly KA. The spectrum of pneumatosis intestinalis. Arch Surg 2003;138:68-75. Pear BL. Pneumatosis intestinalis: a review. Radiology 1998;207:13-9.
  6. Ho LM, Paulson EK, Thompson WM. Pneumatosis intestinalis in the adult: benign to life-threatening causes. AJR Am J Roentgenol 2007;188:1604-13.
  7. Strand V, Burmester GR, Ogale S, Devenport J, John A, Emery P. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. Rheumatology (Oxford) 2012;51:1860-9.
  8. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
  9. Smolen JS, Beaulieu A, Rubbert-Roth A, RamosRemus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
  10. Malaviya AP, Ledingham J, Bloxham J, Bosworth A, Buch M, Choy E, et al. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid ar